A Placebo-Controlled Study of Raloxifene Added to Risperidone in Men with Chronic Schizophrenia
-
Mohammad-Reza Khodaie-Ardakani
,
Mohsen Khosravi
,
Razieh Zarinfard
,
Somayeh Nejati
,
Ali Mohsenian
,
Mina Tabrizi
,
Shahin Akhondzadeh
Abstract
Selective estrogen receptor modulators (SERMs) such as raloxifene have already shown beneficial effects on negative, positive and general psychopathology symptoms in postmenopausal women with schizophrenia. The purpose of the present investigation was to assess the efficacy of raloxifene as an adjuvant agent in the treatment of men with chronic schizophrenia in an 8-week double-blind and placebo-controlled trial. In a randomized, double-blind and placebo-controlled study, forty-six male patients diagnosed with schizophrenia (DSM-IV-TR), were randomized to either raloxifene (120 mg/day) or placebo in addition to risperidone (6 mg/day) for eight weeks. The assessment was performed using the positive and negative symptom scale (PANSS) at baseline, and at weeks 2, 4, 6 and 8. Extrapyramidal symptom rating scale (ESRS) at baseline, weeks 1, 2, 4, 6, 8 and Hamilton depression rating scale (HDRS) at baseline and week 8 were also used to assess extrapyramidal symptoms and depression simultaneously. Forty-two patients completed the trial. The raloxifene group showed significantly greater improvement on the negative subscale (P<0.001), the general psychopathology subscale (P=0.002) and total PANSS score (P<0.001) in comparison to the placebo group at the endpoint. There was no significant difference in the reduction of positive symptoms score between the two group (P=0.525). Extrapyramidal symptom rating scale and Hamilton depression rating scale and frequency of other adverse effects were comparable between two groups.This study indicates raloxifene as a potential adjunctive treatment strategy for chronic schizophrenia in men.
Davidson M, Caspi A, Noy S. The treatment of schizophrenia: from premorbid manifestations to the first episode of psychosis. Dialogues Clin Neurosci 2005;7(1):7-16.
Rössler W, Salize HJ, van Os J, et al. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol 2005;15(4):399-409.
Jablensky A. Epidemiology of schizophrenia: the global burden of disease and disability. Eur Arch Psychiatry Clin Neurosci 2000;250(6):274-85.
Charrier N, Chevreul K, Durand-Zaleski I. The cost of schizophrenia: a literature review. Encephale 2013;39(Suppl 1):S49-56.
Carr VJ, Neil AL, Halpin SA, et al. Costs of schizophrenia and other psychoses in urban Australia: findings from the Low Prevalence (Psychotic) Disorders Study. Aust N Z J Psychiatry 2003;37(1):31-40.
Jackson D, Kirkbride J, Croudace T, et al. Meta-analytic approaches to determine gender differences in the ageincidence characteristics of schizophrenia and related psychoses. Int J Methods Psychiatr Res 2013;22(1):36-45.
McGrath J, Saha S, Welham J, et al. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med 2004;2(1):13.
Leung A, Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr Scand 2000;401(Suppl):3-38.
Usall J, Busquets E, Araya S, et al. Gender differences in schizophrenia. A literature review. Actas españolas Psiquiatr 2000;28(3):178-85.
Sánchez R, Téllez G JL. Age of onset symptoms and gender in schizophrenia spectrum disorders. Biomedica 2012; 2(2):206-13.
Häfner H. Gender differences in schizophrenia. Psychoneuroendocrinology 2003;28(Suppl 2):17-54.
Kulkarni J, Gavrilidis E, Worsley R, et al. Role of estrogen treatment in the management of schizophrenia. CNS Drugs 2012;26(7):549-57.
Smith S. Gender differences in antipsychotic prescribing. Int Rev Psychiatry 2010;22(5):472-84.
Usall J, Suarez D, Haro JM. Gender differences in response to antipsychotic treatment in outpatients with schizophrenia. Psychiatry Res 2007;153(3):225-31.
Goldstein JM, Link BG. Gender and the expression of schizophrenia. J Psychiatr Res 1988;22(2):141-55.
Zeinoddini A, Ahadi M, Farokhnia M, et al. L-lysine as an adjunct to risperidone in patients with chronic schizophrenia: a double-blind, placebo-controlled, randomized trial. J Psychiatr Res 2014;59:125-31.
Hosseini SM, Farokhnia M, Rezaei F, et al. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial. Eur Neuropsychopharmacol 2014;24(6):846-55.
Kulkarni J, Riedel A, de Castella AR, et al. Estrogen - a potential treatment for schizophrenia. Schizophr Res 2001;48(1):137-44.
Hayes E, Gavrilidis E, Kulkarni J. The role of oestrogen and other hormones in the pathophysiology and treatment of schizophrenia. Schizophr Res Treatment 2012;2012:540273.
Kulkarni J. Oestrogen--a new treatment approach for schizophrenia? Med J Aust 2009;190(4 Suppl):S37-8.
Akhondzadeh S, Mokhberi K, Amini H, et al. Is there a relationship between estrogen serum level and symptom severity throughout the menstrual cycle of patients with schizophrenia? Therapy 2005;2:745-51.
Chavez C1, Hollaus M, Scarr E, et al. The effect of estrogen on dopamine and serotonin receptor and transporter levels in the brain: an autoradiography study. Brain Res 2010;1321:51-9.
Landry M, Paolo D. E ffect of chronic estradiol, tamoxifen or raloxifene treatment on serotonin 5-HT 1A receptor. Brain Res Mol Brain Res 2003;112(1-2):82-9.
Huber TJ, Rollnik J, Wilhelms J, et al. Estradiol levels in psychotic disorders. Psychoneuroendocrinology 2001;26(1):27-35.
Kulkarni J, de Castella A, Smith D, et al. A clinical trial of the effects of estrogen in acutely psychotic women. Schizophr Res 1996;20(3):247-52.
Riecher-Rössler A, Häfner H, Dütsch-Strobel A, et al. Further evidence for a specific role of estradiol in schizophrenia? Biol Psychiatry 1994;36(7):492-4.
Kulkarni J. Women and schizophrenia: a review. Aust N Z J Psychiatry 1997;31(1):46-56.
Riecher-Rössler A, Häfner H. Schizophrenia and oestrogens--is there an association? Eur Arch Psychiatry Clin Neurosci 1993;242(6):323-8.
Seeman M V, Lang M. The role of estrogens in schizophrenia gender differences. Schizophr Bull 1990;16(2):185-94.
Akhondzadeh S, Nejatisafa AA, Amini H, et al. Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 2003;27(6):1007-12.
Kulkarni J, de Castella A, Fitzgerald PB, et al. Estrogen in severe mental illness: a potential new treatment approach. Arch Gen Psychiatry 2008;65(8):955-60.
Ghafari E, Fararouie M, Shirazi H. Combination of estrogen and antipsychotics in the treatment of women with chronic schizophrenia. Clin Schizophr Relat Psychoses 2013;6(4):172-6.
Grigoriadis S, Seeman M. The role of estrogen in schizophrenia: implications for schizophrenia practice guidelines for women. Can J Psychiatry 2002;47(5):437-42.
Kulkarni J, Gavrilidis E, Wang W, et al. Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age. Mol Psychiatry 2014. [Epub ahead of print]
Sayed Y, Taxel P. The use of estrogen therapy in men. Curr Opin Pharmacol 2003;3(6):650-4.
Kulkarni J, de Castella A, Headey B, Marston Net al. Estrogens and men with schizophrenia: is there a case for adjunctive therapy? Schizophr Res 2011;125(2-3):278-83.
Chua WL, de Izquierdo SA, Kulkarni J, et al. Estrogen for schizophrenia. Cochrane database Syst Rev 2005;(4):CD004719.
Prentice RL. Postmenopausal hormone therapy and the risks of coronary heart disease, breast cancer, and stroke. Semin Reprod Med 2014;32(6):419-25.
Kulkarni J, Gurvich C, Lee SJ, et al. Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology 2010;35(8):1142-7.
Raveendranathan D, Shivakumar V, Jayaram N, et al. Beneficial effects of add-on raloxifene in schizophrenia. Arch Womens Ment Health 2012;15(2):147-8.
Kianimehr G, Fatehi F, Hashempoor S, et al. Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo controlled trial. Daru 2014;22(1):55.
Huerta-Ramos E, Iniesta R, Ochoa S, et al. Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a double-blind, randomized, placebocontrolled trial. Eur Neuropsychopharmacol 2014;24(2):223-31.
Usall J, Huerta-Ramos E, Iniesta R, et al. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebocontrolled trial. J Clin Psychiatry 2011;72(11):1552-7.
Kulkarni J, Gavrilidis E, Worsley R, et al. The Role of Estrogen in the Treatment of Men with Schizophrenia. Int J Endocrinol Metab 2013;11(3):129-36.
Kirkpatrick B, Fenton WS, Carpenter WT Jr, et al. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 2006;32(2):214-9.
Murphy BP, Chung Y-C, Park TW, et al. Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr Res 2006;88(1-3):5-25.
Littleton-Kearney MT, Ostrowski NL, Cox DA, et al. Selective estrogen receptor modulators: tissue actions and potential for CNS protection. CNS Drug Rev 2002;8(3):309-30.
Huang Y, Huang YL, Lai B, et al. Raloxifene acutely reduces glutamate-induced intracellular calcium increase in cultured rat cortical neurons via inhibition of highvoltage- activated calcium current. Neuroscience 2007;147(2):334-41.
Iritani S. Neuropathology of schizophrenia: a mini review. Neuropathology 2007;27(6):604-8.
Usall J, Huerta-Ramos E, Iniesta R. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebocontrolled trial. J Clin Psychiatry 2011;72(11):1552-7.
Kulkarni J, Gurvich C, Gilbert H, et al. Hormone modulation: a novel therapeutic approach for women with severe mental illness. Aust N Z J Psychiatry 2008;42(1):83-8.
Yaffe K, Krueger K, Cummings SR, Blackwell T, et al. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry 2005;162(4):683-90.
Hayes FJ, Seminara SB, Decruz S, et al. Aromatase inhibition in the human male reveals a hypothalamic site of estrogen feedback. J Clin Endocrinol Metab 2000;85(9):3027-35.
Henderson VW, Lobo RA. Hormone therapy and the riskof stroke: perspectives 10 years after the Women’s Health Initiative trials. Climacteric 2012;15(3):229-34.
| Files | ||
| Issue | Vol 53, No 6 (2015) | |
| Section | Original Article(s) | |
| Keywords | ||
| Estrogen Raloxifene Schizophrenia Men | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
